Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HIV-Infected Patients
  • CME

In this CME-certified activity, Babafemi Taiwo, MBBS, presents a series of topical case studies featuring virologically suppressed patients with HIV infection who require a change in ART and discusses how our expert faculty chose to manage them.
Paul E. Sax, MD
Program Director
Babafemi Taiwo, MBBS
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: March 12, 2018 Expiration: March 11, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate data from switch studies and expert guidelines into patient management strategies
  • Identify virologically suppressed patients who are appropriate candidates to consider a switch to a different antiretroviral regimen
  • Select individualized switch regimens that take account of all relevant patient and regimen factors to optimize safety, efficacy, and tolerability

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has received consulting fees from or served as an advisory board member for AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and has received funds for research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, and Merck.

Faculty

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, and ViiV/GlaxoSmithKline and funds for research support from ViiV/GlaxoSmithKline.

Staff

Jennifer M. Blanchette, PhD

Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients receiving antiretroviral therapy.

Goal

The goal of this activity is to improve participants’ competence in evaluating which of their virologically suppressed patients should consider a switch in regimen and in selecting an optimal new regimen.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately .75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 12, 2018, through March 11, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Listen to downloadable audio from a series of live Webinars by Paul E. Sax, MD, and Brian Wood, MD, in which the use of recently approved integrase inhibitor–based regimens is discussed and audience questions on this subject are addressed.

Released: April 23, 2018

In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Directors Joseph J. Eron, Jr., MD, and Princy N. Kumar, MD, review key HIV data presented at the CROI 2018 meeting.

Released: April 20, 2018

In this downloadable audio of a live Webinar, Chloe Orkin, MBChB, FRCP, MD, provides a rapid update on the clinical impact of new data reported at the Boston meeting.

Chloe Orkin, MBChB, FRCP, MD Released: April 16, 2018

In this slideset, Babafemi Taiwo, MBBS, discusses expert approaches to selecting an HIV switch regimen in a series of cases studies involving HIV-infected patients with virologic suppression on their current ART regimen.

Released: March 13, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Gilead Sciences

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?